Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-24
2006-01-24
Kunz, Gary (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S021800, C514S492000, C424S650000
Reexamination Certificate
active
06989368
ABSTRACT:
The present invention provides methods and compositions for promoting bone regeneration, comprising administration of calmodulin. The method of bone regeneration is applied to subjects having bone disorders characterized by decreased bone mass such as osteopenia and osteoporosis, as well as those suffering from non-union fractures.
REFERENCES:
patent: 5698518 (1997-12-01), Carson et al.
patent: 6190893 (2001-02-01), Shastri et al.
patent: 6287606 (2001-09-01), Bockman et al.
Fujishige et al., “Alteration of cGMP Metabolism During Chondrogenic Differentiation of Chondroprogenitor-like EC Cells, ATDC5,”Biochim. Biophys. Acta, 1452:219-227 (1999). Abstract Only.
Williams et al., “Tamoxifen Inhibits Phorbol Ester Stimulated Osteoclastic Bone Resorption: An Effect Mediated by Calmodulin,”Biochem. Cell Biol., 75:725-723 (2000). Abstract Only.
International Search Report. PCT/US02/41440, United States Patent Office as International Examining Authority.
Gurney Harry C.
McMichael John
Haghighatian Mina
Kunz Gary
Marshall & Gerstein & Borun LLP
Milkhaus Laboratory, Inc.
LandOfFree
Use of calmodulin to promote bone regeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of calmodulin to promote bone regeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of calmodulin to promote bone regeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528900